These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1050 related articles for article (PubMed ID: 15717297)

  • 21. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
    Mai A; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
    Emanuele S; Lauricella M; Tesoriere G
    Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic regulation of airway inflammation.
    Adcock IM; Tsaprouni L; Bhavsar P; Ito K
    Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting histone deacetylase in cancer therapy.
    Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
    Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
    Weidle UH; Grossmann A
    Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic tools in potential anticancer therapy.
    Sebova K; Fridrichova I
    Anticancer Drugs; 2010 Jul; 21(6):565-77. PubMed ID: 20436342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylases and cancer: causes and therapies.
    Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
    Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer treatment of the future: inhibitors of histone methyltransferases.
    Spannhoff A; Sippl W; Jung M
    Int J Biochem Cell Biol; 2009 Jan; 41(1):4-11. PubMed ID: 18773966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
    Fang JY
    J Gastroenterol Hepatol; 2005 Jul; 20(7):988-94. PubMed ID: 15955204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
    Kelly WK; Marks PA
    Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay.
    Wegener D; Hildmann C; Riester D; Schober A; Meyer-Almes FJ; Deubzer HE; Oehme I; Witt O; Lang S; Jaensch M; Makarov V; Lange C; Busse B; Schwienhorst A
    Biochem J; 2008 Jul; 413(1):143-50. PubMed ID: 18384290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Histone-deacetylases inhibitors: from TSA to SAHA].
    Peixoto P; Lansiaux A
    Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity.
    Zubia A; Ropero S; Otaegui D; Ballestar E; Fraga MF; Boix-Chornet M; Berdasco M; Martinez A; Coll-Mulet L; Gil J; Cossío FP; Esteller M
    Oncogene; 2009 Mar; 28(11):1477-84. PubMed ID: 19169274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rational development of histone deacetylase inhibitors as anticancer agents: a review.
    Acharya MR; Sparreboom A; Venitz J; Figg WD
    Mol Pharmacol; 2005 Oct; 68(4):917-32. PubMed ID: 15955865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors: a novel target of anticancer therapy (review).
    Kouraklis G; Theocharis S
    Oncol Rep; 2006 Feb; 15(2):489-94. PubMed ID: 16391874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
    Epping MT; Bernards R
    Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitors--a new tool to treat cancer.
    Somech R; Izraeli S; J Simon A
    Cancer Treat Rev; 2004 Aug; 30(5):461-72. PubMed ID: 15245778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.